Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA), has signed an agreement to acquire the galidesivir antiviral program from US-based BioCryst Pharmaceuticals.
Events
New Stories
-
Island expands portfolio with the acquisition of antiviral
July 10, 2025 - - Latest News -
Orthocell announces first US Remplir sales revenue
July 10, 2025 - - Latest News -
Race secures ethics approvals for Phase 1 trial at two Hong Kong hospitals
July 10, 2025 - - Latest News -
Imagion reports positive feedback from FDA for HER2 breast cancer trial
July 10, 2025 - - Latest News -
Neurizon says FDA provides positive feedback on strategy to lift clinical hold for NUZ-001
July 10, 2025 - - Latest News -
WHO grants official INN for Syntara’s clinical development asset SNT-5505
July 8, 2025 - - Latest News -
AusBiotech welcomes 27 new members in first half of 2025
July 8, 2025 - - AusBiotech